Oligodendrocyte-specific protein (OSP)/claudin-11 has been recently implicated in multiple sclerosis pathophysiology. Yet, the pathogenic autoimmunity against OSP has been poorly investigated. We previously showed that OSP-induced experimental autoimmune encephalomyelitis (EAE) and optic neuritis in SJL/J mice are primarily associated with CD41 T cells reactive against OSP55-80. Dissecting the fine epitope specificity to the level of epitopic residues recognized by OSP-specific encephalitogenic T cells revealed their focused recognition of OSP58M. Accordingly, OSP58M predicted by computer modeling to be a major TCR contact residue shared by the three nonameric core epitopes within OSP55-80, albeit at different MHC-II pockets, was experimentally determined as the primary TCR contact residue crucial for activation and control of encephalitogenic T cells reactive against OSP55-80 or against recombinant OSP. Ala substitution of OSP58M impaired the functional TCR recognition/activation of pathogenic OSP-reactive T cells. Accordingly, the non-stimulatory/ non-encephalitogenic pOSP55-58A-66 analogue not only treated EAE induced by pOSP55-80 but also effectively reversed EAE induced by whole OSP. Thus, the selection/activation and control of OSPpathogenic T cells in H-2 s mice appeared to be dominated by their predetermined focused recognition of OSP58M. Such a focused recognition by OSP-pathogenic T cells, despite their extensive TCR heterogeneity (Kaushansky, N., Zhong, M. C., Kerlero de Rosbo, N., Hoeftberger, R., Lassmann, H. and Ben-Nun, A. 2006 . Epitope specificity of autoreactive T and B cells associated with experimental autoimmune encephalomyelitis and optic neuritis induced by oligodendrocyte-specific protein in SJL/J mice. J. Immunol. 177:7364), may impact profoundly on peripheral self-tolerance to OSP and on altered peptide ligand-mediated immune-specific modulation of the recently described OSP-related autoimmune pathogenesis.
Introduction
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) characterized by primary demyelination and axonal loss. Although the etiology of the disease is unknown, ample evidence suggests that autoimmunity against components of the CNS plays a pathogenic role. Because the disease primarily involves damage to CNS myelin, studies by many laboratories have focused on investigating the involvement of autoimmunity against CNS myelin proteins in the pathogenesis of MS. Characterization of the T-cell reactivity against potential primary encephalitogenic myelin target antigens in MS has provided much of our current understanding of mechanisms related to immunopathogenesis of MS and possible therapeutic strategies. However, in contrast to the extensively studied encephalitogenic target antigens MBP, proteolipid protein (PLP) and more recently, myelin oligodendrocyte glycoprotein (MOG), autoimmunity against oligodendrocyte-specific protein (OSP)/claudin-11 has been poorly investigated. The demonstration of its encephalitogenic potential (1, 2) and the detection of T cells reactive against OSP in MS patients (3) suggest that the autoimmune response to OSP could contribute to the pathogenesis of MS. Therefore, the pathogenic autoimmunity against OSP should also be thoroughly characterized in view of eventual consideration in antigenspecific therapeutic approaches.
OSP is the third most abundant CNS myelin protein, constituting ;7% of total CNS myelin protein. It is a 207 amino acid long, hydrophobic protein with four predicted transmembrane domains that has been localized to CNS myelin (4) (5) (6) and shown by immunoelectron microscopy to be a specific component of tight junction strands in myelin sheaths of oligodendrocytes and Sertoli cells in the testis (7) . Based on sequence homology with claudin family of tight junctions and on its ability to induce tight junctions in transfected fibroblasts, OSP was identified as claudin-11 and was renamed OSP/claudin-11 (7) . The tight junction of the choroid plexus epithelium is also composed of OSP/claudin-11, accompanied by claudin-1 and claudin-2. The function of OSP as a structural protein essential for the formation of tight junctions and maintenance of the compact lamellar structure of CNS myelin was strongly indicated by studies in OSPknockout mice (8) and more convincingly by studies in PLP/ DM20 and OSP/claudin-11 double-knockout mice that presented with markedly abnormal myelin compaction and smaller axon diameters (9) . One of the significant structural difference between CNS and peripheral nervous system myelins is the presence of intra-lamellar tight junctions in CNS myelin. Therefore, an autoimmune attack against OSP would affect the integrity of the myelin sheaths in the CNS only, suggesting the possibility that OSP may be a highly relevant candidate target autoantigen in the CNSspecific disease, MS.
The encephalitogenic potential of OSP was recently demonstrated in H-2 s , H-2 b and ABH mice (1, 2, 10, 11) , and anti-OSP antibodies and OSP-reactive T cells were detected in MS patients (3, 12) . Therefore, OSP can be included in the category of encephalitogenic CNS myelin antigens, which includes MBP, PLP, MOG and myelin-associated oligodendrocytic basic protein (MOBP), considered primary candidate target antigens for the pathogenic autoreactivity in MS. However, in contrast to these myelin target antigens, OSP is a relatively newly uncovered CNS myelin protein and its relevance to MS pathogenesis has only recently been suggested. Accordingly, OSP-induced experimental autoimmune encephalomyelitis (EAE) is also a relatively new model of MS, which has been the subject of only five previous reports (1, 2, 10, 11, 13) . We have recently characterized the autoimmune T-and B-cell responses and the clinical and pathological manifestations associated with OSPinduced EAE and optic neuritis in SJL/J (H-2 s ) and C57Bl/6J (H-2 b ) mice (11, 13) . While chronic OSP-induced EAE in C57Bl/6J was found to be associated with pathogenic T cells primarily directed against the major and minor encephalitogenic regions, OSP179-207 and OSP22-46, respectively (13), the disease in SJL/J mice was associated with pathogenic T cells primarily directed against OSP55-80 and OSP179-207 as major and minor encephalitogenic regions of OSP, respectively (11) . Moreover, the major encephalitogenic epitopes were delineated to OSP194-207 and OSP55-66 for C57Bl/6J and SJL/J mice, respectively (11, 13) .
In this study, we further delineated the major encephalitogenic epitope of OSP to the nonameric core epitope recognized in complex with I-A s by OSP-reactive pathogenic T cells. Structural bioinformatic analyses and experimental data using truncated peptides and peptide analogues showed that OSP-associated pathogenic T-cell autoimmunity is directed primarily to the recognition of OSP58M. Such a focused recognition of OSP58M suggests that this residue governs the selection and control of OSP-related pathogenic T cells. Accordingly, a peptide analogue with the OSP58M substituted to alanine was highly effective in suppression and treatment of OSP-induced EAE.
Methods

Mice
Female SJL/J (H-2 s ) mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA) or obtained from the Weizmann Institute colony. All mice were 2-to 3-month old when used in the experiments. The International Animal Care and Use Committee of the Weizmann Institute has approved the experiments, which were performed in accordance to its relevant guidelines and regulations.
OSP and OSP peptides
The recombinant soluble mouse oligodendrocyte-specific protein (smOSP) was prepared as previously described (2) . The amino acid sequences of peptides used in this study are listed in Table 1 . All peptides were synthesized in the laboratory of Prof. M. Fridkin, Department of Organic Chemistry, The Weizmann Institute of Science, using the Fmoc technique with an automated peptide synthesizer (AMS422; Abimed, Langenfeld, Germany). The purification level of peptides was at least 80%.
T-cell lines and T-cell proliferative responses
Antigen-specific T-cell lines were selected in vitro as described previously (14) from lymph node cells (LNCs) of mice which had been primed 9 days before with antigen (14) . Proliferation assays of selected T-cell lines were performed exactly as previously described (14, 15) .
Active induction of EAE
SJL/J mice were injected s.c. at one site in the flank with 200 ll of emulsion containing 200 lg smOSP or pOSP in CFA with 300 lg M. tuberculosis H37Ra. Mice received 300 ng pertussis toxin in 500 ll PBS in the tail vein immediately and 48 h after immunization. Following the encephalitogenic challenge, mice were observed and scored as previously described (2).
Inhibition assay
Irradiated (25 Gy) SJL/J spleen cells were incubated at 37°C for 3 h with pOSP55-80 (15 lg ml
À1
). The pulsed antigen presenting cells were washed extensively with PBS and added (5 3 10 5 cells per well) to pOSP55-80-specific line T cells (1.5 3 10 4 ) in flat-bottomed 96-well plates; the altered peptide ligands (APLs) were then added at increasing concentration in triplicates. The cultures were incubated for 48 h and processed for measurement of the proliferative response as described above.
Cytokine analysis
Cytokines (IL-2, IFN-c, IL-4 and IL-10) were detected by ELISA according to standard protocols from Pharmingen (San Diego, CA, USA), as described previously (13) . The capture antibodies were rat anti-mouse IL-4 (18191D; PharMingen), rat anti-mouse IL-2 (18161D; Pharmingen), rat antimouse IL-10 (AMC0102; BioSource International, Camarillo, CA, USA) and rat anti-mouse IFN-c (AMC4834; BioSource International). The biotinylated antibodies used were rat anti-mouse IL-4 (18042D), rat anti-mouse IL-2 (18172D), rat anti-mouse IL-10 (18152D) and rat anti-mouse IFN-c (18112D; all from Pharmingen). IL-17 was measured by ELISA using a DuoSet ELISA Development kit (DY421; R&D Systems, Inc., Minneapolis, MN, USA). Transforming growth factor-b (TGF-b) was measured by ELISA according to the standard protocol from R&D Systems, using recombinant human TGF-b sRII/Fc chimera as capture reagent (341-BR; R&D Systems) and biotinylated anti-human TGF-b1 antibody (BAF240; R&D Systems). Recombinant human TGF-b1 (240-B; R&D Systems) was used to construct the standard curve.
Molecular modeling of 'candidate' pOSP52-75/I-A s interactions A model structure of the peptide-binding domain of I-A s was constructed on the basis of the X-ray structure of the closely related I-A K molecule (16), as previously described (17) . Putative core epitopes within the pOSP52-75 fragment were identified as described in ref. 18 . Thus, a 9 3 20 peptidebinding preference matrix was constructed for I-A s based on the shape and chemical character of the peptide-binding cleft in the model and on the available peptide-binding data (19, 20) . The matrix was used in our epitope identifying computer program that estimated a binding score for every nonapeptide within the pOSP52-75 fragments. Several peptides were selected for further analysis in which the peptide-binding DH was estimated. To this end, models of I-A s -peptide complexes were constructed, based on the experimentally observed peptide-binding mode to I-A k . The peptide in each I-A s -peptide complex consisted of the selected core epitope plus two flanking residues at each end. Each complex was immersed in a layer or water and subjected to intermittent dynamics simulations and energy minimizations in order to relieve clashes and to obtain a low energy model. The backbone atoms of the I-A s molecule were tethered to their initial positions during the computations. In addition, several conserved hydrogen bonds between I-A s (Asn76b, Asn63a and Asn70a) and the peptide backbone were used as restraints during the energy computations except in the final energy minimization for each complex. We used the Discovery-3 module in the Accelrys package (Accelrys Inc., San Diego, CA, USA) for energy minimization and dynamics simulations and the consistent valence force field. The binding DH was estimated as the difference between the energy of the complex and the energies of I-A s and the peptide in the final structure. Similar computations were performed for the I-A s core epitope in PLP139-151 complex and the binding energy (DH) for this peptide was used as a reference
Statistical analysis
Comparison of the incidence or mean clinical severity between any two groups of mice that display clinical EAE was done using two-tailed unpaired Student's t-test. P values <0.05 were considered significant.
Results
Prediction of potential major TCR contact residues within the major encephalitogenic region OSP55-80
In a previous study, the OSP55-80 was defined as the major encephalitogenic epitope for SJL/J mice (11) . Moreover, by using N-and/or C-terminal truncated peptides of OSP55-80 we determined pOSP55-71 as the shortest OSP55-80-truncated peptide with the highest encephalitogenic capacity [detailed in (11) Detailed energy computations suggested that registers OSP57-65, OSP60-68 and OSP63-71 are the preferred binding modes to I-A s , as they present similar binding energy to that of the core epitope of the renowned PLP139-151 ( Fig. 1A) which has a relatively very high affinity to I-A s (22) . The computed binding energies of OSP54-62 and OSP59-67 are considerably higher than that of OSP57-65, but not too high to exclude these registers as potential core epitopes, especially when considering the fact that their binding energy is compared with that of PLP139-151. Such a multiplicity of potential nonameric core epitopes renders the definition of a major TCR contact residues that satisfies all nonameric registers and is shared by T cells specific for the major encephalitogenic epitope, OSP55-80, a priori extremely difficult.
However, alignment of the different predicted registers (Fig. 1B) suggested the OSP58M as an important TCR contact residue for three of the potential core epitopes, OSP54-62, OSP57-65 and OSP59-67, albeit at different MHC-class II pockets, p5, p2 and p-1, respectively ( Fig. 1A and B) . Models of the interaction of OSP54-62, OSP57-65 and OSP59-67 with I-A s (Fig. 1C) show that the side chain of OSP58M for each of the three registers points outwards from the MHC-class II-binding cleft, albeit at different pockets, in a manner that may facilitate TCR engagement through OSP58M for the three registers. Thus, the molecular modeling of OSP54-62, OSP57-65 and OSP59-67 with I-A s ( Fig. 1C ) predicts that OSP58M might be a shared major TCR contact residue for these three potential core epitopes. Moreover, and rather interestingly, the other two putative core epitopes, OSP60-68 and OSP63-71, with a high computed affinity for I-A s , but do not involve OSP58, could be excluded as potential functional core epitopes, due to the experimental data showing that both pOSP60-75 and pOSP62-74, harboring OSP60-68 and OSP63-71-putative core epitopes, are non-encephalitogenic and non-stimulatory for the encephalitogenic OSP-reactive line T cells (Fig. 1D) . Thus, the experimental exclusion of OSP60-68 and OSP63-71 left three registers (OSP54-62, OSP57-65 and OSP59-67) as potential functional core epitopes. The proposed positioning of OSP58M within the I-A s -binding cleft as a significant TCR contact residue for the three registers (Fig. 1C) suggests that OSP58M might be the primary TCR contact residue for the encephalitogenic T cells reactive against the major encephalitogenic epitope 55-71 of OSP55-80 encephalitogenic region. Whether OSP58M indeed plays a role as the primary TCR contact residue should be experimentally confirmed.
Experimental confirmation of OSP58M as major TCR contact residue
A set of peptide analogues was synthesized in which all potentially relevant (predicted) TCR contact residues (OSP56C, 58M, 60T, 63Y and 64H) for the three predicted core epitopes within the encephalitogenic peptide OSP55-66 were substituted to alanine (Fig. 2A) . The OSP62L that was predicted to be an I-A s -binding residue (in p9 for OSP54-62, in p6 for OSP57-65 and in p4 for OSP59-67; Fig. 1C ) was also substituted ( Fig. 2A) . Analysis of their capacity to stimulate smOSP-specific or OSP55-80-specific encephalitogenic T line cells showed that only the pOSP55-56A-66 and pOSP55-60A-66 peptide analogues were stimulatory for the OSP55-80 T line cells to a similar extent as the native pOSP55-71 (Fig. 2B) , suggesting that the OSP56C and OSP60T residues play no significant role as major TCR contacts or as major I-A s anchoring residues. Residues OSP63Y and OSP64H may be relevant but not critical TCR contact residues as the Ala-substituted pOSP55-63A-71 and pOSP55-64A-71 analogues were partially stimulatory, stimulating OSP55-80-specific T line cells to ;30-50% compared with stimulation by native pOSP55-71. In contrast, alanine substitution of either OSP58M or OSP62L or both resulted in a profound impairment of the stimulatory capacity of pOSP55-58A-66, pOSP55-62A-66 or the double Alasubstituted pOSP55-58A62A-66 analogues (Fig. 2B) . These experimental data support the models showing the 58M residue positioned as a TCR-binding residue for the three overlapping potential core epitopes (Fig. 1C) in a manner that can be involved in TCR engagement. Accordingly, substitution of this residue by alanine abrogated the stimulation of encephalitogenic OSP55-80-specific T line cells (Fig. 2B) and confirms 58M as a critical residue. Residue 60T is a putative I-A s -binding residue only for register OSP57-65, and the OSP57-65/I-A s model suggested that 60T is not optimally positioned in the large pocket p4. Accordingly, the replacement of 60T by Ala might only slightly weaken but not abrogate epitope binding to I-A s ; indeed, the pOSP55-60A-66 analogue was as stimulatory as the native pOSP55-71. In contrast, 62L is predicted as an I-A s anchoring residue for all three registers [in pockets p9, p6 and p4, respectively, that can be tightly bound in p6 for register OSP57-65 or in p9 for register OSP54-62 (Fig. 1C) ], and its replacement by Ala is likely to significantly weaken the binding to I-A s and impair TCR stimulation. The abrogated capacity of pOSP55-62A-66 to stimulate encephalitogenic OSP55-80-specific T line cells supports this possibility. Overall, these experimental data support the prediction that OSP58M is a major TCR contact residue for the major encephalitogenic epitope of OSP, and the role of OSP58M as primary TCR contact residue is further demonstrated below.
pOSP55-58A-66 and pOSP55-62A-66 are nonencephalitogenic analogues but only pOSP55-58A-66 is highly inhibitory All the non-stimulatory peptide analogues, pOSP55-58A-66, pOSP55-62A-66 and pOSP55-58A62A-66, were tested for their encephalitogenic potential, as compared with the native peptide, pOSP55-66. As shown in Fig. 3 , all mice immunized with pOSP55-66/CFA developed overt clinical EAE. In contrast, none of the mice immunized by the same regimen with pOSP55-58A-66, pOSP55-62A-66 or pOSP55-58A62A-66 developed any clinical signs of EAE. Thus, that the Ala substitution of OSP58M and of OSP62L abrogated the encephalitogenic potential of the peptide analogues further indicated their crucial role for the activation of encephalitogenic T cells reactive against the major encephalitogenic region of OSP in SJL/J mice. To further confirm the predicted role of OSP58M and OSP62L residues as primary TCR contact and crucial I-A s anchoring residues, respectively, we investigated the inhibitory effect of the different peptide analogues on encephalitogenic T cells. The encephalitogenic line T cells specific for the pOSP55-80 (11) were stimulated in vitro with syngeneic irradiated pOSP55-80-pulsed APC in the absence or presence of different concentrations of peptide analogues. Figure 4 shows that pOSP55-63A-71 and pOSP55-64A-71 analogues had no inhibitory effect, and the pOSP55-62A-66 had only a low inhibitory effect (;25% at 80 lg ml À1 ) on the stimulation of pOSP55-80-specific T line cells by native peptide. In contrast, the pOSP55-58A-66 analogue with the predicted primary TCR contact residue altered inhibited the stimulation of encephalitogenic T cells to ;30% already at a concentration as low as 2 lg ml À1 and to ;90% at higher concentration of pOSP55-58A-66 (Fig. 4) . Similar results were obtained when the encephalitogenic line T cells (11) specific for the whole recombinant OSP (data not shown) were stimulated with pOSP55-80-pulsed APC in the presence of the peptide analogues.
The differential inhibitory effect of the non-stimulatory/nonencephalitogenic pOSP55-58A-66 and pOSP55-62A-66 analogues support our modeling (Fig. 1B) , which suggests that 62L is an I-A s -binding residue and 58M is a TCR-binding residue for the potential core epitopes OSP54-62, OSP57-65 and OSP59-67. Moreover, OSP58M that was predicted to be a major TCR contact residue shared by OSP54-62, OSP57-65 and OSP59-67 potential core epitopes appears as a functional primary TCR contact residue that is crucial for the stimulation/activation of the encephalitogenic T cells specific for the major encephalitogenic epitope of OSP. The APLs were then tested for down-modulation of EAE induced by OSP55-71.
pOSP55-58A-66 analogue suppresses pOSP55-71-induced EAE SJL/J mice immunized to develop EAE by s.c. inoculation of pOSP55-71/CFA, were injected i.p. with 100 lg of the nonstimulatory/non-encephalitogenic pOSP55-58A-66, pOSP55-62A-66, pOSP55-58A62A-66 analogues and with native pOSP55-71, or with PBS only, on days 3, 5, 7, 10 and 13 after immunization (n = 5 mice per group). As shown in Fig. 5(A) , while all five mice treated with PBS developed clinical EAE with a mean maximal score of 2.0, the development of EAE in mice treated with pOSP55-58A-66 was dramatically suppressed, with only one of five mice developing relatively weak clinical symptoms of EAE. Figure 5 (B) shows that systemic administration of pOSP55-62A-66 had only a mild effect on the development of pOSP55-71/CFA-induced EAE and its suppressive effect was barely significant. As expected, systemic administration of native pOSP55-71 totally abrogated development of the disease.
These results, together with the inhibitory results (Fig. 4) , strongly support the notion that L62 binds to I-A s , whereas M58 is a TCR contact residue essential for TCR activation of pathogenic T cells. Interestingly, the dual Ala-substituted analogue, pOSP55-58A62A-66, suppressed the development of EAE only to a moderate extent, as compared with that by pOSP55-58A-66, although it also contains the OSP58A substitution. According to the modeling results (Fig. 1C) and the experimental data (Figs. 2B, 3 and 4) , L62 is an important MHC-anchor residue for the three registers and its replacement by Ala may significantly weaken the I-A s -binding ability of pOSP55-58A62A-66 and thereby reduce TCR engagement via pOSP55-58A62A-66/I-A s , explaining its reduced suppressive effect compared with the pOSP55-58A-66 analogue. On the other hand, abrogation of the development of pOSP55-71-induced EAE by the pOSP55-58A-66 analogue (Fig. 5) , together with its effective inhibition of encephalitogenic pOSP55-80-specific T cells (Fig. 4) , strongly suggests that pOSP55-58A-66 is an antagonistic APL potentially effective in down-modulation of OSP-induced EAE in SJL/J mice.
pOSP55-58A-66 down-regulates encephalitogenic T cells in vivo and shifts their cytokine secretion profile SJL/J mice were immunized with pOSP52-75/CFA and injected i.p. (100 lg in 0.5 ml PBS) on days 3, 5 and 7 post-immunization with soluble pOSP55-58A-66, pOSP55-62A-66, native pOSP52-75 or with PBS. The LNCs were ex vivo analyzed for their recall proliferative response to pOSP52-75, prior to the onset of clinical EAE. Figure 6(A) shows that LNC from mice that received soluble pOSP55-58A-66 or native pOSP52-75 showed a clear reduction in their proliferative response to pOSP52-75, as compared with LNC from control mice treated with PBS. The reduction of the proliferative response to pOSP52-75 following treatment with pOSP55-58A-66 or native pOSP52-75 was consistent at all concentrations of pOSP52-75 used for the ex vivo stimulation of LNC. However, the reduced responses were most profound (54% reduction) when LNCs were stimulated in vitro at 2.5 lg ml À1 of pOSP52-75. In contrast, treatment with pOSP55-62A-66 analogue had no suppressive effect on the encephalitogenic pOSP52-75-reactive T cells (Fig. 6A) , consistent with its weak suppressive effect on the development of EAE (Fig. 5B) . Interestingly, systemic administration of pOSP55-58A-66 or pOSP55-62A-66 analogues or native pOSP52-75 had little effect on proliferative response to the purified protein derivative present in CFA that was used as an internal control antigen, suggesting their immune-specific down-regulatory effect on the encephalitogenic T cells. Fig. 5 . Systemic administration of pOSP55-58A-66 analogue abrogates the development of EAE induced by pOSP55-71 representing the major encephalitogenic epitope of OSP. EAE was induced in SJL/J mice by s.c. immunization with pOSP55-71/CFA as described in Methods. On days 3, 5, 7, 10 and 13 after immunization, mice were injected (i.p.) with soluble (100 lg in PBS) with non-stimulatory/non-encephalitogenic peptide analogues. (A) Mice were treated with pOSP55-58A-66, pOSP55-58A62A-66 or PBS. (B) Mice were treated with pOSP55-62A-66, pOSP55-71 or PBS. Mice were scored for EAE severity up to 40 days after immunization. I, incidence. The in vivo down-regulation of pathogenic pOSP52-75-reactive T cells upon systemic administration of pOSP55-58A-66 or native pOSP52-75 was associated with changes in their cytokine secretion pattern. Figure 6 (B) shows that compared with LNC from PBS-treated mice, LNC from mice treated with pOSP55-58A-66 showed a clear, albeit mild, reduction in the secretion of T h 1 (IL-2 and INF-c) and IL-17 cytokines with a pronounced increase in the secretion of T h 2 (IL-4, IL-10 and TGF-b) cytokines. In contrast, LNC from mice treated with pOSP55-62A-66 showed a T h 1 cytokine secretion pattern comparable to that of LNC form PBS-treated mice, but with an elevated secretion of T h 1 (IL-2 and INF-c) and IL-17 cytokines. Expectedly, the LNC from mice treated with native pOSP52-75 also showed a shift toward T h 2 cytokine secretion pattern, although the shift was reflected more in dramatically reduced secretion of INF-c and the increased secretion of IL-10 cytokines. In addition to a shift from pro-inflammatory to anti-inflammatory cytokines, as was previously reported for other APLs (23) (24) (25) (26) , it is likely that other mechanisms that had also been associated with down-regulation of autoagressive T cells upon treatment with soluble APL, such as anergy (27, 28) , apoptosis (27, 29, 30) and up-regulation of regulatory T cells (31) (32) (33) (34) (35) , may also be at play in the down-regulation of pathogenic T cells and suppression of pOSP55-71-induced EAE by soluble pOSP55-58A-66. Detailed investigation of the mechanisms by which pOSP55-58A-66 can down-regulates the pathogenic T cells and suppress the disease are currently being investigated.
Reversal of ongoing smOSP-induced EAE by pOSP55-58A-66
The data presented above pointed to the central role played by OSP58M in the recognition of the major encephalitogenic epitope by OSP-specific pathogenic T cells and indicated that pOSP55-58A-66 is an effective immunomodulatory antagonist for pathogenic T cells reactive against the major encephalitogenic epitope of OSP in SJL/J mice. Additionally, its effective suppression of pOSP52-75-induced EAE inferred a potential therapeutic utility as an antagonist in OSP-associated pathogenesis in H-2 s mice. This possibility was first tested on ongoing disease actively induced by pOSP52-75/CFA. As shown in Fig. 7 , the systemic administration of pOSP55-58A-66 to mice displaying overt clinical EAE resulted in immediate amelioration of the disease. Moreover, the reduction in clinical signs of the disease progressed with time to complete recovery from ongoing EAE actively induced with pOSP52-75. In fact, recovery sustained after the treatment was ceased, and all recovered mice remained free of clinical signs of EAE until the experiment was terminated on day 42 post-immunization.
In view of its effective suppression of the development of EAE and reversal of ongoing disease induced by the major encephalitogenic epitope of smOSP, we investigated the efficacy of OSP55-58A-66 APL in the treatment of ongoing EAE induced by the whole smOSP. SJL/J mice were induced to develop EAE by immunization with smOSP/CFA. On day 22 after immunization, mice with overt clinical EAE were divided into three groups (n = 5 per group) with an equal mean of disease severity. Starting on day 23 post-immunization, mice were treated on alternate days by five i.p. injections of pOSP55-58A-66, smOSP or PBS alone. As shown in Fig. 8 , systemic administration of pOSP55-58A-66 dramatically decreased the clinical signs of EAE, resulting in a complete reversal of EAE clinical manifestations, while control mice treated with PBS remained with chronic EAE, albeit clinical severity was spontaneously reduced with time (Fig. 8) . It is worth noting that the reversal of clinical manifestations upon treatment with pOSP55-58A-66 was comparable to that upon treatment with native smOSP, which, in contrast to the antagonist APL, has the inherent risk of activating OSP-reactive T cells pathogenic for H-2 s mice.
Discussion
In view of the likely possibility that autoimmunity against OSP can also play a role in the pathogenesis of MS, detailed investigation into the pathogenic T-cell autoimmunity against OSP is of major significance in eventual consideration of antigen-specific therapeutic approaches to OSP-related pathogenic autoimmunity. It may also contribute to the understanding of the pathophysiology and etiology of MS. The study presented above dissected the major encephalitogenic epitope OSP55-71 within the major encephalitogenic region of OSP (OSP55-80) to the level of single residues most relevant for activation of OSP-specific encephalitogenic T cells. Molecular modeling and experimental analyses showed that a single epitopic residue (OSP58M) within the major encephalitogenic region plays a central role as a TCR contact residue crucial for functional TCR recognition/activation of pathogenic T cells reactive against the major encephalitogenic region of OSP. Accordingly, the OSP55-58A-66 APL was highly effective in suppressing the development of EAE, as well as in reversing ongoing disease induced by OSP52-75, representing the major encephalitogenic epitope of OSP for SJL/J mice. Moreover, and most relevant for therapeutic utility, systemic administration of OSP55-58A-66 APL was highly effective in the suppression of EAE induced by the whole smOSP (data not shown), as well as in a complete reversal of the clinical manifestations of ongoing chronic EAE induced by smOSP. We note that the APL treats EAE despite the presence of an additional, albeit minor, encephalitogenic epitope located within OSP179-207 of smOSP (11) . Thus, both the activation and control of OSP-related pathogenic autoimmunity in SJL/J mice appeared to be governed by a single epitopic residue due to their dependence on the recognition of OSP58M. The focused recognition of OSP58M by pathogenic OSPspecific T cells is particularly intriguing in view of their potential recognition of overlapping core epitopes and in view of a previous study reporting that SJL/J OSP-specific pathogenic line T cells selected for reactivity against smOSP, or against the major encephalitogenic region OSP55-80, are extensively diverse in their TCRVb expression (11) . While a shared major TCR contact residue may explain to a certain extent their focused recognition of OSP58 despite their potential specificity to several overlapping nonameric core epitopes, it is quite difficult to understand how the OSP-specific pathogenic T cells are highly focused on a single epitopic residue, contrary to their extensive TCR heterogeneity. Most studies defining APLs are aimed at the potential clinical utility of the APL approach to immune-specific modulation of pathogenic T-cell autoimmunity. Indeed, the focused recognition on OSP58 greatly facilitated the APL-mediated downmodulation of OSP-associated EAE. However, the questions of whether there is a significant role for such focused recognition by pathogenic OSP-specific T cells expressing diverse TCRs (11) in normal physiology and its physiological benefit are of no less significance.
Due to the sequestration of OSP in the CNS (and testicles) as an immune-privileged sites and to a relatively late expression of OSP during ontogeny (36) , it is likely that T cells reactive against OSP may have escaped thymic selection, similar to T cells reactive against MOG (37, 38) . This suggests that pathogenic autoimmune OSP-specific T cells are physiologically maintained under self-tolerance mainly via peripheral tolerance mechanisms. We hypothesize that the pathogenic T-cell autoimmunity against OSP is primarily directed against the major encephalitogenic region, OSP55-80, and is focused on recognition of OSP58M, as the result of a natural (non-thymic) selective force that may allow a more effective peripheral control of OSP-specific pathogenic T cells that have escaped thymic selection. At present, there is no direct evidence supporting this possibility. However, focused epitopic residue recognition by pathogenic autoimmune T cells is apparently not an isolated case for OSP-related pathogenic T-cell autoimmunity in SJL/J mice. Pathogenic T-cell autoimmunity against an autoantigen focused to a single epitopic residue of the autoantigen, despite the extensive TCR heterogeneity of the pathogenic T cells, was recently demonstrated in other models of EAE. Encephalitogenic T cells reactive against MOG (18) or OSP (2, 13) in H-2 b mice, or against MOBP (39) in H-2 s mice, were also shown to be primarily directed against their respective major encephalitogenic epitope and to be highly focused to recognizing a single (or two) epitopic residue within their respective major encephalitogenic epitope. Thus, in MOGor OSP-induced EAE in H-2 b mice, or in MOBP-induced EAE in SJL/J mice, the different pathogenic T-cell populations reactive against MOG or OSP in H-2 b mice, or MOBP in H-2 s mice, share the MOG44F (18), OSP192Y (13) or the MOBP21F/27P (39) as their major TCR contact residue, respectively, despite their heterogeneous TCRs. Accordingly, a single peptide analogue with alteration of the appropriate single epitopic residue of the major encephalitogenic epitope of MOG, OSP or MOBP was also sufficient for immunospecific down-modulation of EAE induced by the respective whole myelin autoantigen (13, 18, 39) . The studies showing that a single residue mutation of MOG (MOG44F to Ala) totally abrogated the encephalitogenic potential of MOG for H-2 b mice (18) strongly suggest that, at least for H-2 b mice, an effective activation of pathogenic autoimmune T cells reactive against the whole MOG is focused on their interaction with the epitopic residue MOG44F.
Interestingly, the pathogenic T cells in OSP-induced EAE in both H-2 b (13) and H-2 s mice (this study) were focused on the recognition of a single epitopic residue, albeit to a different one within the respective major encephalitogenic epitopes. This further reiterates the possibility of natural selective force driving focused recognition of a major epitopic residue by TCR heterogeneous autoimmune pathogenic T cells. Thus, it appears that in OSP-induced EAE in H-2 s mice or in H-2 b mice, similar to MOBP-or MOG-induced EAE, the pathogenic autoimmune T cells are in fact preselected to be dominated by the recognition of a single epitopic residue, both for their activation and control, due to their highly focused epitope specificity. Such pathogenic T-cell autoimmunity focused to a recognition of one or two epitopic residues by a natural selective force may facilitate a more 'focused control' of potentially pathogenic antigenspecific autoimmune T cells in the periphery. This potential focused control may be of immense advantage in maintaining 'peripheral control' of pathogenic autoimmune T cells that have escaped central tolerance mechanisms in the thymus due to the late expression during ontogeny of their autoantigen in immune-privileged sites such as the CNS or the testes, as in the case of OSP (7).
Regardless of whether the focused recognition of OSP58M by OSP-specific pathogenic T cells facilitates peripheral self-tolerance of potentially pathogenic autoimmune OSP-reactive T cells, the effective reversal of ongoing EAE by OSP55-58A-66 APL suggests the potential clinical utility of APL-mediated therapy for OSP-related autoimmune pathogenesis that has been recently associated with MS (3, 12) and investigated in mice (1, 2, 10, 11, 13). 
